Information Provided By:
Fly News Breaks for March 5, 2018
MRTX
Mar 5, 2018 | 08:42 EDT
Citi analyst Yigal Nochomovitz raised his price target for Mirati Therapeutics to $37 saying the company's KRAS G12C inhibitor, "albeit preclinical, seems to have the right stuff." We understand several pharma players have expressed substantial early interest in Mirati's KRAS program, Nochomovitz tells investors in a research note. He added the program to his model with a 10% probability of success and calls it a "must watch." The analyst keeps a Buy rating on Mirati Therapeutics.
News For MRTX From the Last 2 Days
There are no results for your query MRTX